Parkinson's Disease Trial, Recruiting NCT05182892 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT05182892
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with idiopathic Parkinson's syndrome (a specific type of Parkinson's disease) according to recognised Movement Disorders Society guidelines.
  • People who have received deep brain stimulation (DBS) surgery on both sides of the brain in an area called the subthalamic nucleus.
  • People who had their DBS surgery at least 3 months before joining the trial.
  • People who are able to give their written consent to participate.
  • People who are fluent in Swiss-German or German.
  • People whose speech difficulties (dysarthria) appear to have been caused or worsened by their DBS treatment — either noticed around the time of the DBS surgery, or speech that improves when the stimulation strength is turned down during routine check-ups.

Who may not be able to join:

  • People whose speech difficulties are caused by a condition other than Parkinson's disease or DBS, such as a stroke or a muscle condition like myasthenia.
  • People who have been clinically diagnosed with aphasia (a condition affecting the ability to understand or produce language).
  • People who are unable to follow the study procedures due to language barriers, psychological conditions, or dementia. A memory and thinking test (called the MoCA) will be used, and people who score 20 or below out of 30 points will not be eligible.
  • People whose Parkinson's medication was changed in the four weeks before joining certain parts of the trial (parts 1 and 3).
  • People whose DBS device settings were changed in the four weeks before joining certain parts of the trial (parts 1 and 3).
  • People experiencing depression with active thoughts of suicide.
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Krack, Prof., Insel Gruppe AG, University Hospital Bern

Phone: 31 632 21 68

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
13 December 2021
Est. completion
30 November 2025

Where this trial is recruiting

🇨🇿 Czechia 🇨🇭 Switzerland

Primary endpoints

Part 1: Identification of the most sensitive and specific speech variables; Part 1: Identification of the most sensitive and specific speech variables; Part 2, Speech analysis: Investigation of spatial overlap of volume of tissue activated (VTA) and the corticobulbar/corticospinal tract; Part 2, Speech analysis: Investigation of spatial overlap of VTA and the dorsolateral (sensorimotor) STN; Part 3: Perceptual speech ratings; Part 3: Perceptual speech ratings; Part 3: Perceptual speech ratings; Part 3: Automated speech analysis; Part 3: Automated speech analysis; Part 3: Automated speech analy...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov